VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from the European Institute of Oncology in Milan. After his talk at the St Gallen breast cancer conference he discussed criteria for individualizing optimal endocrine adjuvant treatments with Oncology Times reporter Sarah Maxwell.
You may also like...
ASCO Audio Journal of Oncology in Advance – June 1st, 2007 – reporting from: American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles 2 Jun, 2007 Prior Chemotherapy: No Bar to Checkpoint Inhibition in Mesothelioma 26 Apr, 2015 Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation 14 Jan, 2020 PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression 31 Oct, 2018
- Previous story Genetic Tests for Breast Cancer Late Recurrence Risk—Not Yet Ready for Prime Time
- Next story Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014